MIRM vs WSBC Comparison

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Wesbanco Inc is a bank holding company. Through its subsidiaries, it offers a full range of financial services, including retail banking, corporate banking, personal and corporate trust services, brokerage services, mortgage banking, and insurance. WesBanco operates one commercial bank, WesBanco Bank, which runs scores of branches. The company's reportable segments are Community Banking, which derives key revenue, and Trust and Investment Services. The Community Banking segment offers various banking products and services through various delivery channels, including commercial demand, individual demand, and time deposit accounts; commercial, mortgage, and individual installment loans; and certain non-traditional offerings, such as insurance and securities brokerage services.